CXCL9 and neoplasm: To evaluate the geospatial distribution of T lymphocyte infiltration into treated tumors, we resected tumor tissue on day 15 following treatment with either sham control or combination AAV6-CXCL9 with anti-PD-1 ICB, where lymphocytes are identifiable through endogenous EGFP expression.